Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection
NCT ID: NCT01136161
Last Updated: 2013-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
95 participants
INTERVENTIONAL
2010-06-30
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The trial will be double-blinded, randomized and placebo-controlled with 96 subjects (48 HIV- and 48 HIV+ subjects).
Three different RUTI® doses and placebo will be tested, randomizing assigned both in HIV+ and HIV- subjects. Each subject will be randomized to receive one of the four treatments (placebo, 5, 25, 50 μg), after completion of one month INH pre-treatment (one tablet of 300mg/day, vp.o.). Each subject will receive two administrations of the same treatment, 28 days apart. Subjects will be monitored until one month after the second inoculation with RUTI®.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Efficacy and Safety of the Concomitant of RUTI® Immunotherapy With the Standard Treatment in TB Patients
NCT05136833
Safety of RUTI® Vaccination in MDR-TB Patients
NCT02711735
Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)
NCT04919239
Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis
NCT05455112
Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers
NCT00546273
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RUTI 5 micrograms of FCMtb in HIV -
n=12
RUTI
dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
RUTI 25 micrograms of FCMtb in HIV -
n=12
RUTI
dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
RUTI 50 micrograms of FCMtb in HIV -
n=12
RUTI
dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
RUTI Matching Placebo in HIV -
n=12
RUTI Matching Placebo
Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
RUTI 5 micrograms of FCMtb in HIV +
n=12
RUTI
dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
RUTI 25 micrograms of FCMtb in HIV +
n=12
RUTI
dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
RUTI 50 micrograms of FCMtb in HIV +
n=12
RUTI
dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
RUTI Matching Placebo in HIV +
n=12
RUTI Matching Placebo
Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RUTI
dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
RUTI
dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
RUTI
dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
RUTI Matching Placebo
Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. No evidence of active TB (Section 8).
3. No clinically significant finding at the discretion of the investigator.
4. Willingness to undergo an HIV test.
5. Resident in or near trial site for the duration of the trial.
6. Willingness to allow the investigators to discuss the patient's medical history with his usual doctor or HIV physician.
7. No donation of blood for 56 days prior to screening and agreement to refrain from blood donation during the trial.
8. Willing and able to provide written informed consent.
9. Positive tuberculin skin test (TST +), (≥5 mm induration) and Quantiferon TB Gold positive result (according to manufacturers instructions).
10. Reliable contraception to be used by female subjects during the clinical trial.
* HIV antibody positive.
* CD4 count ≥350 cells/mL3 on a single CD4 count at the period of screening.
* Subjects on anti-retroviral treatment can be included if clinically stable.
Exclusion Criteria
2. Use of any investigational or non-registered drug, vaccine, or medical device other than the trial vaccine within 30 days prior to dosing of trial vaccine, or planned use during the trial period.
3. Administration of chronic (defined as more than 14 days) immunosuppressive drugs within six months of vaccination and required throughout the duration of the trial (for corticosteroids this means prednisolone or equivalent at ≥ 0.5 mg/kg/day).
4. Female of child bearing potential who intends to become pregnant during the trial.
5. Females who are pregnant, lactating, or of child bearing potential with a blood HCG positive result 24-48 hours at the screening period, or prior to every injection of RUTI®.
6. Any AIDS defining illness according to the CDC classification system for HIV infection.
7. Presence of active (previously undiagnosed) TB or being on TB treatment.
8. Suspected or known current alcohol abuse (alcohol intake questionnaire.
9. Suspected or known substance abuse.
10. Presence of any underlying disease, specifically autoimmune disease, asthma, angioedema, bleeding disorders, uncontrolled hypertension and diabetes, and any other disease that compromises the diagnosis and evaluation of response to the vaccine, excluding HIV.
11. Administration of immunoglobulins and/or any blood products within three months prior to the planned administration of the vaccine.
12. Any history of anaphylaxis in reaction to vaccination and/or other medication.
13. Investigator assessment of lack of understanding or willingness to participate and comply with all requirements of the trial protocol.
14. Any other finding which in the opinion of the investigator would significantly increase the risk of having an adverse outcome from participating in the trial.
* Weight less than 40 kg.
* Known or suspected hypersensitivity to INH.
* Self reported chronic liver disease or symptoms suggesting active hepatitis (jaundice, nausea, vomiting, right upper quadrant pain, dark urine, pale stools).
* Alcohol use exceeding 28 units per week (men) or 21 units per week (women) (see alcohol intake questionnaire, Appendix 17.2).
* History of convulsions.
* History of psychosis.
* Peripheral neuropathy grade 2 or greater.
* Three months post-partum.
* Concomitant medication with phenytoin, carbamazepine; warfarin; theophylline; disulfiram; selective serotonin re-uptake inhibitor antidepressants (e.g. citalopram, fluoxetine, paroxetine, sertraline); oral ketoconazole or itraconazole.
16. Additional exclusion criterion for HIV negative groups:
• Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia.
17. Additional exclusion criterion for HIV+ groups • CD4 count \< 350 cells/mL3.
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Parexel
INDUSTRY
Archivel Farma S.L.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
André S Nell, MD
Role: PRINCIPAL_INVESTIGATOR
Parexel Int. Bloemfontein
Pere Joan Cardona, MD, PhD
Role: STUDY_CHAIR
Archivel Farma S.L.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Parexel Int. Bloemfontein
Bloemfontein, , South Africa
Parexel Int. George
George, , South Africa
Parexel Int. Port Elizabeth
Port Elizabeth, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gil O, Diaz I, Vilaplana C, Tapia G, Diaz J, Fort M, Caceres N, Pinto S, Cayla J, Corner L, Domingo M, Cardona PJ. Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PLoS One. 2010 Apr 6;5(4):e10030. doi: 10.1371/journal.pone.0010030.
Cardona PJ. Revisiting the natural history of tuberculosis. The inclusion of constant reinfection, host tolerance, and damage-response frameworks leads to a better understanding of latent infection and its evolution towards active disease. Arch Immunol Ther Exp (Warsz). 2010 Feb;58(1):7-14. doi: 10.1007/s00005-009-0062-5. Epub 2010 Jan 5.
Vilaplana C, Montane E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine. 2010 Jan 22;28(4):1106-16. doi: 10.1016/j.vaccine.2009.09.134. Epub 2009 Oct 22.
Domingo M, Gil O, Serrano E, Guirado E, Nofrarias M, Grassa M, Caceres N, Perez B, Vilaplana C, Cardona PJ. Effectiveness and safety of a treatment regimen based on isoniazid plus vaccination with Mycobacterium tuberculosis cells' fragments: field-study with naturally Mycobacterium caprae-infected goats. Scand J Immunol. 2009 Jun;69(6):500-7. doi: 10.1111/j.1365-3083.2009.02251.x.
Cardona PJ. A dynamic reinfection hypothesis of latent tuberculosis infection. Infection. 2009 Apr;37(2):80-6. doi: 10.1007/s15010-008-8087-y. Epub 2009 Mar 23.
Gil O, Vilaplana C, Guirado E, Diaz J, Caceres N, Singh M, Cardona PJ. Enhanced gamma interferon responses of mouse spleen cells following immunotherapy for tuberculosis relapse. Clin Vaccine Immunol. 2008 Nov;15(11):1742-4. doi: 10.1128/CVI.00255-08. Epub 2008 Sep 30.
Guirado E, Gil O, Caceres N, Singh M, Vilaplana C, Cardona PJ. Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis. Clin Vaccine Immunol. 2008 Aug;15(8):1229-37. doi: 10.1128/CVI.00094-08. Epub 2008 Jun 4.
Vilaplana C, Ruiz-Manzano J, Gil O, Cuchillo F, Montane E, Singh M, Spallek R, Ausina V, Cardona PJ. The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays. Scand J Immunol. 2008 Jun;67(6):610-7. doi: 10.1111/j.1365-3083.2008.02103.x. Epub 2008 Apr 4.
Cardona PJ. New insights on the nature of latent tuberculosis infection and its treatment. Inflamm Allergy Drug Targets. 2007 Mar;6(1):27-39. doi: 10.2174/187152807780077282.
Guirado E, Amat I, Gil O, Diaz J, Arcos V, Caceres N, Ausina V, Cardona PJ. Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect. 2006 Apr;8(5):1252-9. doi: 10.1016/j.micinf.2005.12.004. Epub 2006 Jan 27.
Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb). 2006 May-Jul;86(3-4):273-89. doi: 10.1016/j.tube.2006.01.024. Epub 2006 Mar 20.
Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, Diaz J, Vilaplana C, Tapia G, Ausina V. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine. 2005 Feb 3;23(11):1393-8. doi: 10.1016/j.vaccine.2004.09.008.
Nell AS, D'lom E, Bouic P, Sabate M, Bosser R, Picas J, Amat M, Churchyard G, Cardona PJ. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One. 2014 Feb 26;9(2):e89612. doi: 10.1371/journal.pone.0089612. eCollection 2014.
Related Links
Access external resources that provide additional context or updates about the study.
Fundació Institut Investigació en Ciències de la Salut Germans Trias i Pujol homepage
Archivel Farma, S.L. homepage
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RUTISAPH2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.